Chapter 3 │ Page 67 control and anti-tumor immunity. Given its favorable safety profile and localized application, NTP forms a strong candidate for clinical translation, particularly for R/M HNSCC patients with high comorbidities and limited treatment options. Future studies will focus on evaluating the e icacy of NTP-CDDP in established tumors, with the ultimate goal of integrating this approach into first-line therapeutic strategies, potentially in combination with ICIs, to improve clinical outcomes in this challenging patient population.
RkJQdWJsaXNoZXIy MTk4NDMw